Long responders to estramustine monophosphate. Report of two cases and literature review
Adelys Castillero1, Miguel Ramírez-Backhaus1, Inmaculada Iborra1
1Urology Department. Valencian Oncology Institute Foundation. FIVO. Spain.
Objective:
Estramustine is an stable estradiol and nitrogenated mustard conjugatewith antymicotic properties. Currently, with the appearance of chemotherapy and new molecules, estramustin acetate is not a drug of choice for castration resistant prostate cancer.
Methods:
We describe two patients with castration resistant prostate cancer under treatment with estramustine acetate and complete biochemical response and stable disease. We review the literature to elucidate if the drug should be stopped and changed for the new molecules that have demonstrated survival increase.
Results:
To our knowledge, there are not data in the literature to either solve the questions posed or shed light regarding cumulative toxicity due to prolongued use of estramustine acetate.
Conclusions:
We recognize that these clinical cases do not translate that estramustine acetate is a first line treatment for patients with CRPC. Nevertheless, they translate the heterogeneity of CRPC. It would be interesting to investigate the combination of new agents with estramustine acetate as well as the search of biomarkers that enable selection of candidates who could respond to estramustine acetate.
Related Concept Videos
04:33Spinal Hernia Repair and Cauda Equina Repositioning After Lumbar Decompression under Three-Dimensional Microscopy: A Case Report and Literature Review
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Data Reporting and Recording
08:06Testing for Metacognitive Responding Using an Odor-based Delayed Match-to-Sample Test in Rats
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:

